Conclusion: IL1RL1 gene expression is associated with eosinophilic SA, whereas NLRP3 inflammasome expression is highest in patients with neutrophilic SA. T H 2-driven eosinophilic inflammation and neutrophil-associated inflammasome activation might represent interacting pathways in patients with SA. (J Allergy Clin Immunol 2018;141:560-70.)
Key words: Severe asthma, eosinophil, neutrophil, exhaled nitric oxide, T H 2, inflammasome, C-reactive protein, IL-33 receptor, IL1a, Severe asthma (SA) has been defined as asthma that remains uncontrolled despite high-intensity treatment. 1 This umbrella definition encompasses the heterogeneity that has been analyzed in terms of clinical and biomarker-based phenotypes. 2 Sputum granulocyte cell counts have been used to phenotype SA. In 2 analyses of SA cohorts, the sputum eosinophil cell count has proved useful in distinguishing several asthma phenotypes. 3, 4 Furthermore, in addition to eosinophilic inflammation, other inflammatory phenotypes have been proposed: neutrophilic, mixed neutrophilic and eosinophilic, and paucigranulocytic inflammation. 5 Molecular phenotyping of sputum cells might help define asthma endotypes by means of delineation of transcriptomic and proteomic signals that relate to sputum granulocytic inflammation. 6 Expression of T H 2-related transcripts, such as IL4, IL5, and IL13, in sputum cells has been used to define T H 2-high asthma, which comprised up to 70% of a mild/moderate asthmatic group associated with eosinophilic inflammation. 7 In association with neutrophilic asthma, increased levels of brain-derived neurotrophic factor, IL-1b, and macrophage inflammatory protein 3a/CCL20 have been reported in induced sputum supernatants from patients with SA, 3 with the same study reporting nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3 (NLRP3) inflammasome upregulation. 8 Therefore both T H 2 and non-T H 2 mechanisms could underlie the heterogeneity of asthma.
We now present sputum transcriptomic and proteomic analysis from SA cohorts recruited in the Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes (U-BIOPRED) study. 9 We determined the relationship between the inflammatory subtypes indicated by the sputum granulocytic distribution and the differentially expressed genes. We show a predominance of eosinophilic inflammation in patients with SA compared with those without SA that is associated with enhanced T H 2 cytokine protein expression and IL-1 receptor-like 1 (IL1RL1) mRNA expression. Increased expression of IL-1 and IL-18R family members and of the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1 (NLRP1), NLRP3, and nucleotide-binding oligomerization domain (NOD)-like receptor C4 (NLRC4) inflammasomes was associated with the neutrophilic subtype. Inflammasome inhibition using CRID3 prevented airway hyperresponsiveness (AHR) and lung neutrophilic and eosinophilic inflammation together with reduced expression of IL-1b and T H 2 cytokines. Some of the results of these studies have been previously reported in abstract form. 10 
METHODS
Detailed methods are provided in the Methods section in this article's Online Repository at www.jacionline.org.
U-BIOPRED SA cohorts
Four adult groups were recruited from 11 European countries: group A, nonsmoking patients with severe asthma (SAn); group B, smokers and ex-smokers severe asthma (SAsm); group C, nonsmoking patients with mild/moderate asthma (MMAs); and group D, healthy nonsmoking control subjects (Table I) . 9 The study was approved by the ethics committees for each of the recruiting centers, and participants provided written and signed informed consent forms. Participants underwent spirometry; hematologic profiles, including blood eosinophil and neutrophil counts; and fraction of exhaled nitric oxide (FENO) values. Allergic status was obtained by means of either skin prick testing or measurement of specific IgE levels to 6 common aeroallergens. Fig E1 in this article' s Online Repository at www.jacionline.org shows the CONSORT diagram for the sputum, bronchial brushing, and bronchial biopsy samples, and the overlap between samples from each patient is shown in Table E1 in this article's Online Repository at www.jacionline.org.
Sputum induction and analysis
Sputum induction was performed, as previously described. 11 Cell pellets were used to prepare RNA by using the miRNeasy Mini Kit (Qiagen, San Diego, Calif) before analysis with Affymetrix GeneChip HT HG-U1331 PM microarrays (Affymetrix, Santa Clara, Calif). Raw data were quality assessed by using the Almac Pipeline and Pre-processing Toolbox (Almac, Craigavon, United Kingdom) and preprocessed by using robust multiarray average normalization. Expression of inflammasomeand T H 2-associated genes was confirmed by using quantitative RT-PCR (RT-qPCR) in a restricted number of subjects in each of the 4 groups. One thousand one hundred twenty-nine analytes were quantified by using SOMAscan (v3; SomaLogic, Boulder, Colo; www.somalogic.com) 12 and reported as relative fluorescence units, cross-plate calibrated, and median normalized.
Abbreviations used
ADEPT Signatures summarized by using gene set variation analysis
We evaluated gene expression related to IL-13 activation using gene set variation analysis (GSVA), which calculates sample-wise enrichment scores (ESs) irrespective of any group labels, thus enabling implementation of null hypothesis-based statistical analysis. 13 By annotating each subject with a summary of the genes related to each disease mechanism, GSVA was used to compare the expression of a set of genes between groups. We compiled 2 gene sets related to asthma (see Table E2 in this article's Online Repository at www.jacionline.org), and the ESs were calculated for each gene set for each subject.
Mouse model of SA
Male BALB/c mice were sensitized subcutaneously with saline or 100 mg of house dust mite (HDM) extract with or without complete Freund adjuvant. Two weeks after sensitization, mice were challenged with saline or 25 mg of HDM through intranasal instillation.
14 Twenty-four hours before challenge, mice were dosed with CRID3 (200 mg/kg administered intraperitoneally), and acetylcholine airway responsiveness (AHR) and bronchoalveolar lavage (BAL) samples were collected 24 hours after challenge. 15 This dose of CRID3 was selected because pharmacokinetics studies showed that it provided complete inhibition of inflammation for 24 hours.
Data analysis
Continuously distributed data were summarized by using either the mean 6 SEM or, if skewed, the median and interquartile range; distributions were compared by using a Kruskall-Wallis test. Binary data were summarized by using the proportion and percentage, and a Pearson x 2 test was applied to test homogeneity of groups. All tabulated P values are raw and unadjusted. Analyses were performed with R software (version 3.3.0; R Core Team, 2016).
Data sets were uploaded and curated in the tranSMART system. 16 Differentially expressed gene data analysis was performed on ArrayStudio software (OmicSoft, Cary, NC), applying a general linear model adjusting for age and sex (see Fig E2 in this article's Online Repository at www.jacionline.org). The false discovery rate (FDR) was used to address multiple test correction in genes with a fold change of greater than 2 or less than 2. Some genes had an FDR of less than 0.05 but did not reach a fold change of greater than 2 or less than 2. In the GSVA analysis 1-way ANOVA was used to analyze the ES differences among group means and post hoc analysis by using the Tukey test. g:Profiler was used for pathway analysis of differential gene and protein expression.
For analysis of the differences in inflammatory groups determined based on sputum granulocytic cell counts in each of the 4 cohorts, we used a x 2 test. For validation of gene expression, we used the Airway Disease Endotyping for Personalized Therapeutics (ADEPT) cohort. 17 
RESULTS

Sputum characteristics
From the 363 subjects who undertook sputum induction, 265 patients produced samples of sufficient quality for subsequent inflammatory cell counts (Table I) . Granulocyte counts in the healthy subjects were used to define phenotypes in this study. We defined the normal range as the 95th percentile of granulocyte ACQ5, Asthma Control Questionnaire5; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; IQR, interquartile range; NA, not applicable; OCS, Oral corticosteroid. *P value, SAsm versus SAn; P value, MMA versus SAn; àP value, healthy control versus SAn; §P value, MMA versus SAsm; kP value, healthy control vs SAsm; and {P value, healthy control vs MMA. Number of symbols represents the strength as follows: P < .05, P < .01, and P < .001 for 1, 2, and 3 symbols, respectively.
counts expressed as a percentage of total counts of the healthy control group. The inflammatory categories were thus defined as eosinophilic (> _1.49%), neutrophilic (> _73.6%), mixed eosinophilic and neutrophilic (> _1.49% and > _73.6%), and paucigranulocytic (within normal values; Fig 1) . The eosinophilic category was highest in the 2 SA groups, with the SAn cohort at 50% and the SAsm cohort at 53%, compared with 40% in the MMA group (P < .001, Fig 1) . Neutrophilic inflammation did not vary significantly among the 3 groups (Fig 1) . We then analyzed the distribution of clinical features and biomarkers across the 4 defined sputum inflammatory groups, as shown in Table E3 in this article's Online Repository at www. jacionline.org. The paucigranulocytic group showed the highest FEV 1 (percent predicted) and lowest Asthma Control Questionnaire 5 scores compared with the various granulocytic groups. There was no significant difference in FEV 1 or Asthma Control Questionnaire 5 scores among the eosinophilic, neutrophilic, and mixed granulocytic groups. The mixed granulocytic and eosinophilic groups had higher levels of total IgE (P < .01), exhaled nitric oxide (P < .001), and blood eosinophil counts (P < .001) than the neutrophilic and paucigranulocytic groups.
Receiver operating characteristic analysis of peripheral blood eosinophils and FENO values as biomarkers of sputum eosinophilia was performed by using the pROC R package, which applies bootstrapping to produce the curves and estimate CIs. 18 For peripheral blood eosinophils, the highest combination of sensitivity (73.6%) and specificity (77.9%) was reached at 200/ mL (area under the curve, 78.3%). For FENO values, the highest combination of sensitivity (77.9%) and specificity (69.6%) was observed at a threshold of 24. IL-1 receptor family and inflammasome-associated genes are upregulated in sputum cells in patients with SA
We next determined whether gene expression profiling could provide evidence for pathways that could distinguish different asthma phenotypes. We analyzed transcriptomic profiles of the 120 samples across the 4 cohorts that had sufficient good-quality RNA for analysis (see Fig E4 in this article's Online Repository at www.jacionline.org). Adjusting for age and sex of the subjects, 801 gene probes were differentially expressed in the SAn cohort compared with healthy control subjects (286 upregulated and 515 downregulated, 2-fold change, FDR < 0.05). When compared with MMAs, there were 172 differentially expressed gene probes (42 were upregulated and 130 were downregulated). Upregulated genes associated with the IL-1 receptor (IL-1R) family and the inflammasome were found to be differentially expressed in the SAn cohort, and these included IL-1 receptor-like 1 (IL1RL1), IL-18 receptor 1 (IL18R1), NOD-like receptor family pyrin domain containing 3 (NLRP3), IL receptors type I (ILRL1) and type II (IL1RL2), IL-1 receptor-associated kinase 3 (IRAK3), and IL-18 receptor accessory protein (IL18RAP ; Table II ). Pathway analysis compared across asthma severity indicated that the top dysregulated pathway between patients with SA and healthy control subjects was oxidative phosphorylation (see Table E4 in this article's Online Repository at www.jacionline.org) and that the downregulated genes were mostly associated with the phagosome pathway.
Differential expression of IL-1R family and inflammasome-associated genes according to sputum granulocytes
We next examined whether expression of these IL-1R-related genes was associated with specific sputum granulocyte subtypes. Initial analysis shows that IL18R1, IL1R2, IRAK3, and IL1RL1 were all upregulated in patients with SA (Fig 2, A-D) . In contrast, expression of IL18R1, IL1R2, and IRAK3 was highest in the eosinophilic, mixed, and neutrophilic inflammatory types compared with the paucigranulocytic group and healthy volunteers (Fig 2,  E-G) . In contrast, IL1RL1 expression was only significantly higher (2-fold change, FDR < 0.05) in the eosinophilic and mixed granulocytic groups. Furthermore, IL1RL1 expression correlated well with the IL-13-induced T H 2 gene signature expression (Fig 3  and see jacionline.org). Importantly, expression of the Charcot-Leyden crystal protein gene (CLC) was also significantly correlated with sputum eosinophil counts (r 5 0.82, P < 10 216 ) and with the IL-13-induced signature (r 5 0.47, P < 10
IL-18R1
IL-1R2 NLRP3
IRAK3
27
; Fig 3) . 19 We next examined expression of genes associated with the inflammasome pathway. Expression of NLRP3, a subset of the NOD-like receptors and activator of IL-1b generation, was increased in the eosinophilic, neutrophilic, and mixed inflammatory groups compared with the healthy nonasthmatic groups (Fig  2, H) , with its expression being highly significantly correlated only with sputum neutrophils (Table III) . There was a good correlation between NLRP3 expression and that of caspase 1 (CASP1), CASP4, and CASP5 expression and that of NOD2 and Toll-like receptor 2 (TLR2; see Table E6 in this article's Online Repository at www.jacionline.org). In addition, there was a significant correlation between NLRP3 gene expression and members of the IL-1R family (see Table E6 ).
Expression of other inflammasome family members was also associated with neutrophilic asthma. Thus, although expression of CASP1, CASP4, CASP5, NLRP1, NLRC4, and NOD2 mRNA was not upregulated according to asthma severity, expression of these genes was significantly enriched in patients with (Fig 3, C) and sputum inflammation (eosinophilic, mixed granulocytic, neutrophilic, or paucigranulocytic; Fig 3, D) . Each dot represents a single subject. Statistical significance is reported as an FDR of less than 0.05.
Eosinophilic Mixed Neutrophilic Pauci Healthy
Eosinophilic Mixed Neutrophilic Pauci Healthy The associations maintain nominal significance for patients with SA versus healthy control subjects, with a modest decrease in effect size after adjustment for neutrophil and eosinophil proportions in statistical models. IL1R2 and IL18R1 also maintain an FDR of less than 0.05 after adjustment. Therefore, although the inflammasome-associated gene associations are in part a consequence of differences in cellular composition of sputum samples, the statistical models adjusting for cellular composition suggest that expression levels of these genes can also be increased on a per-cell basis as well (see Table E7 in this article's Online Repository at www.jacionline.org).
T H 2-associated genes are upregulated in subsets of asthmatic patients
We also examined whether there was an association between IL-1R-related genes and T H 2 inflammation. The IL-13-induced epithelial cell signature 19 was used to examine T H 2-high asthma because IL4, IL5, and IL13 mRNA levels were less than the level of quantification in the gene arrays. We defined subjects as having T H 2-high asthma if their ESs for the IL-13-induced gene signature were greater than those of the 95th percentile of expression in the healthy control group. The highest proportion of patients with a T H 2-high signature was seen in the SAn cohort (group A, 67%), followed by the SAsm cohort (group B, 35%) and the MMAs (group C, 25%). ESs were significantly higher in the SAn and SAsm cohorts and in the mixed, eosinophilic, and neutrophilic groups compared with healthy control subjects (Fig  3) . There was a modest correlation between the IL-13-induced gene signature and sputum eosinophil counts (r 5 0.38, P < 10
24
). In the 86 participants in whom both sputum transcriptomic and SOMAscan data were available, there was a significant correlation between the IL-13-induced T H 2 gene signature and sputum periostin levels (r 5 0.46, P < 10 26 ). The correlation with the IL-13-induced T H 2 signature ES was most significant with IL1RL1 (r 5 0.49, P < 10
27
) and NLRP3 (r 5 0.49, P < 10 27 ) but seen to a much lesser extent with IL18R1, IL18RAP, IL1R2, and IRAK3 (Table III) . There was a significant positive correlation between IL18R1, IL1R2, IL18RAP, and IRAK3 and neutrophil percentages in sputum and between IL1RL1 and IL18R1 and eosinophil percentage sputum counts (Table III) . Expression of the IL-1 family and T H 2 genes was validated by using RT-qPCR on cDNA from 9 sputum cell samples that showed the highest and lowest expression of the IL-1R family from each of the 4 cohorts, which showed a good correlation in sputum samples (see Fig E7 and Table E8 in this article's Online Repository at www.jacionline.org).
Analysis of IL-1b and T H 2 cytokines and other analytes in sputum, as detected by using SOMAscan IL-1b, but not IL-1a, protein levels were increased in sputum supernatants of the SAn and SAsm cohorts compared with those of healthy control subjects (fold change, 1. . When analyzed by using sputum granulocytes, IL-1b and IL-1a protein concentrations were significantly higher in neutrophilic and mixed granulocytic patients compared with the other groups (Fig 4) . IL-1b and IL-1a protein levels were also significantly correlated with sputum neutrophil counts (r 5 0.37 [FDR < 10 24 ] and r 5 0.24 [FDR < 0.01], respectively) but not with sputum eosinophil counts.
There was a significant difference (FDR < 0.05) in IL-4 and IL-5 but not IL-13 protein expression between the SA groups and healthy control subjects, as determined by using SOMAscan analysis (see Table E9 in this article's Online Repository at www. jacionline.org). IL-5 expression was increased in both the SAsm and SAn cohorts, whereas IL-4 expression was increased in the SAn cohort but reduced in the SAsm cohort.
In addition to IL-1a and IL-1b, there were a number of proteins/analytes that were significantly upregulated in sputum from patients with SA, including several acute-phase proteins, and eosinophil-and neutrophil-associated mediators (see Table  E10 in this article's Online Repository at www.jacionline.org). Pregnancy-associated plasma protein A (pappalysin 1) and serum amyloid P component were the top differentially expressed analytes in the SAn and SAsm cohorts compared with healthy control subjects and were highly correlated with sputum eosinophil counts (r 5 0.87 and 0.60, respectively). Sputum periostin and mast cell tryptase g levels were also correlated with sputum eosinophil counts (r 5 0.55 and 0.56, respectively), but the former were significantly upregulated only in the SAn cohort compared with healthy control subjects.
The top neutrophil-associated analytes were b-endorphin and peptidoglycan recognition protein 1, followed by the neutrophil granule proteins azurocidin, elastase and proteinase-3, and CXCL-8. Pathway analysis of the differentially expressed sputum analytes demonstrated highly significant changes in inflammatory, innate immune, infection, and proliferation pathways in patients with SA compared with healthy control subjects (see Table E11 in this article's Online Repository at (Fig 5, C) , neutrophils (Fig 5, D) , eosinophils (Fig 5, E) , macrophages (Fig 5, F) , and lymphocytes (Fig 5, G) . HDM and Complete Freund adjuvant (CFA) were administered, followed by exposure to HDM aerosol and/or pretreatment with CRID3. *P < .05, **P < .01, and ***P < .001 and #P < .05 and ##P < .01 versus HDM/CFA saline group (Fig 5, A) . *P < .05, **P < .01, and ***P < .001 (Fig 5, B-D) .
www.jacionline.org). The nuclear factor kB pathway was also significantly upregulated in patients with SA compared with MMAs (P 5 .0438).
IL-1R family-associated gene signature in airway biopsy specimens and epithelial brushings
To examine whether the differential expression of IL-1R-associated genes was limited to sputum or was seen in other airway compartments, we examined their expression in patients who also underwent a bronchoscopic procedure for bronchial brushings and bronchial biopsies. There was no differential mRNA expression in these genes between groups, as determined based on severity or granulocyte content, and the derived IL-1R family-associated gene signature was only significantly enriched in bronchial brushings of patients with SA compared with those of healthy control subjects (FDR 5 3.56 3 10 25 ). There was no enrichment of the IL-1R family-associated gene signature in biopsy specimens. The IL-1R family-associated gene signature ESs in 101 subjects who had both sputum and blood transcriptomic data were significantly but weakly correlated (r 5 0.297, P 5 .0027).
Validation in the ADEPT cohort
By using GSVA analysis, the ADEPT SA group 17 exhibited the highest enrichment of the U-BIOPRED IL-1R family-associated gene signature (see Fig E8 and Table E12 and the Results section in this article's Online Repository at www.jacionline.org).
Role of the NLRP3 inflammasome in modulating inflammation in a mouse model of SA To examine the role of the NLRP3 inflammasome, we used the complete Freund adjuvant HDM model of severe corticosteroidresistant asthma. HDM challenge significantly increased AHR, BAL cell inflammation, and BAL expression of IL-1b and T H 2 cytokines and of chemokines related to neutrophil and eosinophil infiltration (see Table E12 : saline 11.6 6 2.5 vs CRID3 1.3 6 0.5, P < .001; Fig 5) . This was associated with a marked reduction in expression of IL-1b, T H 2 cytokines, and many eosinophil-, neutrophil-and macrophage-associated chemokines (see Table E13 in this article's Online Repository at www.jacionline.org).
DISCUSSION
The main finding of this study is increased expression of IL-1R family members in sputum of patients with SA, both smokers and nonsmokers. We demonstrated that expression of the NLRP1, NLRP3, and NLRC4 inflammasomes is upregulated in patients with neutrophilic asthma, although NLRP1 and NLRC4 mRNA expression is not enhanced in patients with SA per se. IL-1b protein levels and levels of known NLRP3 activators, such as C5a, 21 were increased in the sputum of patients with SA and particularly in those with neutrophilic inflammation. There was no activation of NLRP3 or enrichment of IL-1R family genes in bronchial brushings or biopsy specimens. Finally, inhibition of the NLRP3 inflammasome by using CRID3 prevented the development of AHR, BAL neutrophilia, and eosinophilia and was associated with reduced expression of IL-1b, T H 2 cytokines, and neutrophil-and eosinophil-associated chemokines. Sputum IL1RL1 expression was associated with severe, particularly eosinophilic, asthma and with T H 2 cytokine protein but not gene expression. IL1RL1 mRNA was not upregulated in bronchial biopsy specimens or brushings in patients with SA.
Both SA groups had a greater degree of sputum eosinophilic and mixed inflammation compared with MMAs. The sputum eosinophil percentages reported here are similar to those in other studies in patients with SA, 22 although the percentages of neutrophilic and mixed granulocytic patients differ, which might reflect the different cutoff values selected according to the healthy control subjects recruited. Data from the Severe Asthma Research Program cohort 23 indicate that patients with neutrophilpredominant or mixed granulocytic asthma had more severe disease, as confirmed in our study. Patients with neutrophilic or mixed granulocytic sputum profiles were the most symptomatic patients, and those with mixed granulocytic disease had the worst lung function and the highest use of regular oral corticosteroids and the highest incidence of nasal polyps, although this was not significant, as judged by means of ANOVA. However, currently used clinical markers, such as blood eosinophil counts and FENO values, were unable to clearly distinguish between the various inflammatory profiles in sputum. 24 FENO values and blood eosinophil counts were similar and highest in the eosinophilic and mixed group but equally low in the neutrophilic and paucigranular groups, mirroring the findings of Hastie et al. 24 Receiver operating characteristic curves indicated that these biomarkers have a fair sensitivity and specificity for detecting sputum eosinophilia.
Although there was a significant correlation between the IL-13-induced signature, a marker of T H 2-high asthma, and sputum eosinophil counts, there were significant numbers of subjects with high eosinophil counts with little or no IL-13-induced/T H 2 signatures, as well as subjects with high IL-13-induced/T H 2 ESs with either low eosinophilic inflammation or enriched neutrophilic inflammation. Levels of serum periostin 25 were highest in the 2 SA groups, particularly in those with eosinophilic or mixed inflammation. Thus a more complex interaction between eosinophils and T H 2 asthma exists, and the delineation of non-T H 2 eosinophilic asthma requires further investigation.
The partitioning of IL-1R family members and the NLRP3 inflammasome contrasts with that of the T H 2-high endotype. Thus although IL18R1, IL1R2, IRAK3, and NLPR3 gene expression was highest in the eosinophilic, neutrophilic, and mixed inflammatory groups, IL1RL1 (also known as IL33R or ST2) expression was only increased in the eosinophilic and mixed groups. This clearly reflects the link between IL33R and T H 2-type inflammation because IL-33 produced from epithelial cells has been reported to drive T H 2-associated cytokine expression. 26 A previous report indicates increased IL1RL1 mRNA and protein expression in the epithelium of patients with SA. 27 We were unable to confirm the difference in IL1RL1 gene expression, which might reflect the difference in inhaled corticosteroid use across groups.
Eosinophilic inflammation is linked to the T H 2-high endotype, 28 and we examined this relationship indirectly at the mRNA level using a previously described IL-13-induced/T H 2-high signature because we were unable to detect significant levels of IL-4, IL-5, and IL-13 mRNA in asthmatic sputum. IL-5, but not IL-4 and IL-13, protein levels were significantly increased in sputum from patients with SA compared with that from healthy control subjects. Using a gene signature induced by IL-13 in epithelial cells, 19 we found that 67% of the SAn cohort and only 35% of the SAsm cohort had an enrichment for this signature in sputum cells. A similar percentage of T H 2-high subjects has been reported previously, 7 although we were unable to confirm the reported association with the sputum marker CCL26 (eotaxin 3) because this was not measured in the SOMAscan panel. We were also unable to confirm a correlation between sputum highmobility group box 1 and receptor for advanced glycation endproducts levels with asthma severity and sputum neutrophilia. 29 We found no difference in sputum high-mobility group box 1 levels across the cohorts, and soluble receptor for advanced glycation end-products levels were reduced 2.5-fold in patients with SA compared with healthy control subjects.
Inflammasome activation in bronchial brushings or biopsy specimens was not observed, suggesting that sputum cells are likely to be critical sensors for inflammasome activation in patients with stable SA. A network of inflammatory and innate immune changes occurs in sputum, as detected by using our SOMAscan analysis, confirming the previous reports of inflammasome activation in patients with SA. 8, 30 This indicates that the activator or activators of the inflammasome might come from the external environment, such as the microbiome, and might not reach the epithelium. This is supported by recent reports of microbial dysbiosis in patients with SA. 31, 32 The presence of increased levels of complement C5a in sputum supernatants would further support this possibility. Other drivers for inflammasome activation are unclear but might involve mitochondrial reactive oxygen species, 33 and there is now clear evidence that mitochondrial oxidative stress is important in various mouse models of allergen challenge. 34, 35 Sputum and nasal sampling are less invasive means of assessing airway biology. In a preliminary analysis we examined similarities between our sputum data and the nasal RNA sequencing data from Poole et al. 36 Nine genes were differentially expressed in both studies, and when we used the top 50 upregulated genes in nasal brushings as a gene signature for GSVA analysis in our sputum samples, we observed a significant enrichment, particularly in the SAn cohort (0.46; FDR 5 1.7 3 10 25 ). This suggests that nasal brushings can provide further insight into the airway biology of asthma, although further work is needed to confirm this.
Our observations have been confirmed by the array results using RT-qPCR and by observing similar levels of expression in the independent ADEPT cohort. Another strength of our study is measurement of 1129 analytes in sputum supernatants, which pointed to several potential activators of the inflammasome and highlighted stimulation of key pathways involved in inflammation, innate immunity, and infection in these patients with stable SA, which is not seen in MMAs, despite all subjects receiving inhaled corticosteroids, oral corticosteroids, or both.
We have demonstrated that inflammasome activation is essential in regulation of AHR and inflammation in a mouse model of severe steroid-insensitive asthma. In an ovalbumininduced T H 2-dominant allergic asthma model, NLRP3
2/2 mice showed less eosinophilic and lymphocytic infiltration in the lungs, with lower levels of T H 2-related cytokines than wild-type mice. These authors suggested that nuclear NLRP3 could induce IL-4 transcription. 37 We showed that loss of NLRP3 activation by CRID3 also prevented T H 2 cytokine expression and eosinophilia. The pathophysiologic mechanisms underlying SA are complex, and interpatient variability in inflammasome-T H 2 interactions might exist. Clustering analysis of gene expression profiles should lead to further subdivisions of SA.
In summary, eosinophilic and mixed neutrophilic/eosinophilic inflammation, as measured in sputum, was greater in patients with SA compared with that in MMAs. Many differentially expressed genes in patients with SA were members of the IL-1R family, and NLRP3 expression was greatest in patients with neutrophilic asthma, whereas eosinophilic asthma was associated with IL1RL1 expression. Inhibition of NLRP3 in a mouse model of SA prevented both neutrophilia and eosinophilia and ablated AHR. This indicates a potential therapeutic effect of anti-IL-1 approaches in patients with neutrophilic asthma.
